COLUMBUS, Ohio–(BUSINESS WIRE)–#AI—Deep Lens, Inc., an AI-driven digital pathology company focused on clinical trial recruitment at the time of diagnosis, announced today the company has appointed Kevin Whiteley as Vice President of Provider Sales. Whiteley is a diagnostics and medical device executive with extensive experience in general management, marketing management, sales leadership, and business development. Prior to joining Deep Lens, Whiteley was the Vice President, Market and Business Development for Leica Biosystems.
“Kevin has more than 10 years of prominent experience in digital pathology, leading global market development, sales, and strategic partnerships,” said Simon Arkell, president and co-founder of Deep Lens. “We look forward to his contributions in expanding service, sales, and marketing to support demand for VIPER, our leading AI-enabled digital pathology platform, which is designed to deliver the right cancer diagnoses faster and accelerate oncology trial recruitment and timelines.”
“Delays in patient recruitment for clinical trials add significant costs to drug development programs,” said Whiteley. “I was impressed with how Deep Lens empowers the pathologist in clinical trial recruitment to identify eligible patients at the time of their diagnosis and help fast-track trial enrollment. I look forward to helping Deep Lens meet the current and anticipated demand and growth for its disruptive approach to clinical trial recruitment.”
Previously, Whiteley held multiple positions at Leica Biosystems from leading product management teams in digital pathology to being responsible for global strategic partnership agreements and software solutions revenue growth. He has also served as a corporate liaison for top cancer centers and worldwide KOL engagements. Prior to his positions at Leica, Whiteley held leadership positions at American Hospital Supply Corp., Alaris Medical Systems, R2 Technology, and Aperio. He has served on the board of the Digital Pathology Association.
About VIPER
The company’s flagship technology, called VIPER (Virtual Imaging for Pathology Education and Research), was originally developed for research purposes in Columbus, Ohio where it was the de-facto platform for global oncology studies including The Cancer Genome Atlas Project (TCGA) and others, before being commercialized by Deep Lens. VIPER combines artificial intelligence (AI) with advanced pathology workflows while also facilitating peer-to-peer collaboration and patient identification for clinical trials. The ultimate aim is to provide users with fast and accurate information, along with expert consultation, for better patient care and advanced clinical research. VIPER is available free-of-charge to pathology groups worldwide. Sign up for a free VIPER account here.
About Deep Lens
Deep Lens has extended one of the world’s first digital pathology cloud platforms, VIPER, to include artificial intelligence, enhanced pathology workflow support and collaboration capabilities. In addition to providing essential workflow support to pathology teams, Deep Lens offers the most precise and timely source for identifying sites and patients for sponsored clinical trials. For more information, visit www.deeplens.ai and connect on LinkedIn and Twitter @DeepLens_AI.
Contacts
Jessica Yingling, Ph.D., President, Little Dog Communications Inc.
jessica@litldog.com, +1.858.344.8091